Company news

Atara Biotherapeutics, Inc. news in 2021

Atara Biotherapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

December 12, 2021

Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021

December 8, 2021

European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

November 29, 2021

Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress

November 3, 2021

Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

October 27, 2021

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

October 3, 2021

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)

September 26, 2021

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

August 8, 2021

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

August 8, 2021

Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

June 6, 2021

Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

May 9, 2021

Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress

May 3, 2021

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress

February 28, 2021

Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

February 17, 2021

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

January 3, 2021

Calls in 2021

Decks in 2021